Watching Globalstar; Traders Circulate Government SmartOne C And SPOT Trace Tracking Devices Request

https://sam.gov/opp/270aef1b0b3a4471a53d9508fb4d8268/view

https://sam.gov/opp/270aef1b0b3a4471a53d9508fb4d8268/view

Total
0
Shares
Related Posts
Read More

FDA Accepted Submission of Supplemental New Drug Application for LYNPARZA in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that a supplemental New Drug Application (sNDA) for LYNPARZA in combination with abiraterone and prednisone or prednisolone has been accepted and granted priority review by the U.S.

AZN